BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27927666)

  • 1. Epigenetic biomarkers in progression from non-dysplastic Barrett's oesophagus to oesophageal adenocarcinoma: a systematic review protocol.
    Nieto T; Tomlinson CL; Dretzke J; Bayliss S; Dilworth M; Beggs AD; Tucker O
    BMJ Open; 2016 Dec; 6(12):e013361. PubMed ID: 27927666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of epigenetic biomarkers in progression from non-dysplastic Barrett's oesophagus to oesophageal adenocarcinoma.
    Nieto T; Tomlinson CL; Dretzke J; Bayliss S; Price MJ; Dilworth M; Beggs AD; Tucker O
    BMJ Open; 2018 Jun; 8(6):e020427. PubMed ID: 29961009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.
    Kastelein F; van Olphen SH; Steyerberg EW; Spaander MC; Bruno MJ;
    Gut; 2016 Apr; 65(4):548-54. PubMed ID: 25903690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life measures in dysplastic Barrett's oesophagus are comparable to patients with non-dysplastic Barrett's oesophagus and do not improve after endoscopic therapy.
    Ratcliffe E; Britton J; Heal C; Keld R; Murgatroyd M; Willert R; McLaughlin J; Hamdy S; Ang Y
    BMJ Open Gastroenterol; 2023 Apr; 10(1):. PubMed ID: 37041020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exercise and the Prevention of Oesophageal Cancer (EPOC) study protocol: a randomized controlled trial of exercise versus stretching in males with Barrett's oesophagus.
    Winzer BM; Paratz JD; Reeves MM; Whiteman DC
    BMC Cancer; 2010 Jun; 10():292. PubMed ID: 20550712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
    Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
    Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barrett's oesophagus: Current controversies.
    Amadi C; Gatenby P
    World J Gastroenterol; 2017 Jul; 23(28):5051-5067. PubMed ID: 28811703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
    Quera R; O'Sullivan K; Quigley EM
    Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.
    Duits LC; Phoa KN; Curvers WL; Ten Kate FJ; Meijer GA; Seldenrijk CA; Offerhaus GJ; Visser M; Meijer SL; Krishnadath KK; Tijssen JG; Mallant-Hent RC; Bergman JJ
    Gut; 2015 May; 64(5):700-6. PubMed ID: 25034523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis.
    Eusebi LH; Cirota GG; Zagari RM; Ford AC
    Gut; 2021 Mar; 70(3):456-463. PubMed ID: 32732370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for esophageal adenocarcinoma and precancerous conditions (dysplasia and Barrett's esophagus) in patients with chronic gastroesophageal reflux disease with or without other risk factors: two systematic reviews and one overview of reviews to inform a guideline of the Canadian Task Force on Preventive Health Care (CTFPHC).
    Hamel C; Ahmadzai N; Beck A; Thuku M; Skidmore B; Pussegoda K; Bjerre L; Chatterjee A; Dennis K; Ferri L; Maziak DE; Shea BJ; Hutton B; Little J; Moher D; Stevens A
    Syst Rev; 2020 Jan; 9(1):20. PubMed ID: 31996261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced expression of αGlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma--a possible biomarker to predict the malignant potential of Barrett's oesophagus.
    Iwaya Y; Hasebe O; Koide N; Kitahara K; Suga T; Shinji A; Muraki T; Yokosawa S; Yamada S; Arakura N; Tanaka E; Nakayama J
    Histopathology; 2014 Mar; 64(4):536-46. PubMed ID: 24117499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of α-methylacyl-CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus.
    Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
    Histopathology; 2013 Nov; 63(5):630-9. PubMed ID: 24004067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only--what is the clinical significance?
    Meining A; Ott R; Becker I; Hahn S; Mühlen J; Werner M; Höfler H; Classen M; Heldwein W; Rösch T
    Gut; 2004 Oct; 53(10):1402-7. PubMed ID: 15361485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are screening and surveillance for Barrett's oesophagus really worthwhile?
    Sharma P; Sidorenko EI
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i27-32. PubMed ID: 15711005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metallothionein in human oesophagus, Barrett's epithelium and adenocarcinoma.
    Coyle P; Mathew G; Game PA; Myers JC; Philcox JC; Rofe AM; Jamieson GG
    Br J Cancer; 2002 Aug; 87(5):533-6. PubMed ID: 12189552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular biology of Barrett's cancer.
    Atherfold PA; Jankowski JA
    Best Pract Res Clin Gastroenterol; 2006; 20(5):813-27. PubMed ID: 16997163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study.
    Timmer MR; Martinez P; Lau CT; Westra WM; Calpe S; Rygiel AM; Rosmolen WD; Meijer SL; Ten Kate FJ; Dijkgraaf MG; Mallant-Hent RC; Naber AH; van Oijen AH; Baak LC; Scholten P; Böhmer CJ; Fockens P; Maley CC; Graham TA; Bergman JJ; Krishnadath KK
    Gut; 2016 Oct; 65(10):1602-10. PubMed ID: 26104750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin.
    Fayter D; Corbett M; Heirs M; Fox D; Eastwood A
    Health Technol Assess; 2010 Jul; 14(37):1-288. PubMed ID: 20663420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.